Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026221 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00026221: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00026221 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026221, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying giving bevacizumab together with interferon alpha to see how well it works compared to giving bevacizumab alone in treating patients with metastatic malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Interferon alpha may interfere with the growth of the cancer cells and slow the growth of the tumor. Combining bevacizumab with interferon alpha may kill more tumor cells.
Interventions
- BIOLOGICAL Bevacizumab
- BIOLOGICAL Recombinant Interferon Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2001-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026221
The ClinicalTrials.gov registry entry for NCT00026221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00026221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026221 about?
NCT00026221 is a clinical study titled "Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma". This randomized phase II trial is studying giving bevacizumab together with interferon alpha to see how well it works compared to giving bevacizumab alone in treating patients with metastatic malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. S...
What is the current status of trial NCT00026221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2001-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00026221?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Recombinant Interferon Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00026221?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.